Evolution of extracorporeal membrane oxygenation trigger criteria in COVID-19 acute respiratory distress syndrome

Deitz, Rachel L.; Thorngren, Christina; Seese, Laura; Ryan, John P.; Ramanan, Raj; Sánchez, Pablo G.; Murray, Holt

doi:10.1016/j.jtcvs.2022.09.066

Cited by 2 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 To date, despite numerous kinds of treatments, such as Paxlovid, 7 Remdesivir, 8 dexamethasone, 9 convalescent plasma, 10 and vaccine, 11 have been tested among COVID-19 patients, the mortality among hospitalized patients remains high, especially among patients who admitted to the intensive care unit (ICU), with rates ranging from 35% to 66%. 3,[12][13][14][15] Because of the universal concerns about the virus and the disturbing nature of its accelerated spread, finding effective treatments has become a priority.…”

Section: Introductionmentioning

confidence: 99%

“…The disease of patients who are infected with SARS‐CoV‐2 progresses rapidly, and affected patients may get through acute respiratory distress syndrome (ARDS), 2 respiratory failure, 3 coagulopathies, 4 multiorgan dysfunction (MOD), 5 and even death within a short time 6 . To date, despite numerous kinds of treatments, such as Paxlovid, 7 Remdesivir, 8 dexamethasone, 9 convalescent plasma, 10 and vaccine, 11 have been tested among COVID‐19 patients, the mortality among hospitalized patients remains high, especially among patients who admitted to the intensive care unit (ICU), with rates ranging from 35% to 66% 3,12–15 . Because of the universal concerns about the virus and the disturbing nature of its accelerated spread, finding effective treatments has become a priority.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect and safety of mesenchymal stem cells for patients with COVID‐19: Systematic review and meta‐analysis with trial sequential analysis

Zhang

Shao

Liu

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

The objective of this study was to assess whether mesenchymal stem cells (MSCs) therapy could offer survival advantages for patients with novel coronavirus disease 2019 ). An electronic search of PubMed, Embase, Cochrane Library, Web of Science, WanFang, and CNKI was performed from December 1, 2019 to December 25, 2022. The primary outcome was all-cause mortality. Trial sequential analysis (TSA) was conducted in this meta analysis. Besides, subgroup analysis and meta-regression was performed using a random-effects model to find the potential sources of heterogeneity.Seventeen randomized controlled trials (RCTs) involving a total of 1073 patients with COVID-19 were included in this study. Compared with the control group, patients in the MSCs groups were associated with significantly reduced all-cause mortality (MSCs 18.4% vs. control 25.5%; risk ratio [RR] 0.73; 95% confidence interval [CI] 0.59-0.90; p = 0.004; I² = 0%). For all secondary outcomes, there wasn't significant improvement in the experimental group versus the control group regarding symptom remission rate (53.2%, 201/378 vs. 46.5%, 164/353; RR 1.15; 95% CI 1.00-1.32; p = 0.05; I² = 43%), but the pooled analysis revealed significant differences between the groups in length of hospital stay (MD: −3.82, 95% CI: −5.87 to −1.77; p = 0.0003, I2 = 0%), requirement of invasive mechanical ventilation (RR 0.52; 95% CI 0.33-0.82; p = 0.005; I 2 = 0%) and post-CRP level (MD: −31.61; 95% CI −46.74 to −16.49; p < 0.0001). Moreover, regarding the incidence of adverse events (AEs) (RR 0.73; 95% CI 0.35-1.52; p = 0.39; I² = 44%) and serious adverse events (sAEs) (RR 0.87; 95% CI 0.40-1.92; p = 0.73; I² = 39%), no significant differences were observed between MSCs and control groups. The TSA analysis showed that the result of all-cause mortality might be false-positive result. Based on the pooled results in this study, compared with standard treatment, MSCs therapy

show abstract